Health Care & Life Sciences » Pharmaceuticals | Inspyr Therapeutics Inc.

Inspyr Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
2017
Cash & Short Term Investments
2,345.00
3,587.00
2,316.00
2,465.00
547.00
10
Other Current Assets
77.00
163.00
197.00
114.00
112.00
5
Total Current Assets
2,422.00
3,750.00
2,513.00
2,579.00
659.00
15
Net Property, Plant & Equipment
12.00
14.00
12.00
12.00
4.00
4
Intangible Assets
136.00
118.00
101.00
84.00
68.00
50
Other Assets
3.00
3.00
3.00
3.00
3.00
-
Total Assets
2,573.00
3,885.00
2,629.00
2,678.00
734.00
69
ST Debt & Current Portion LT Debt
105.00
105.00
105.00
-
-
Accounts Payable
728.00
1,270.00
-
-
-
Other Current Liabilities
2,468.00
1,250.00
2,427.00
4,586.00
4,163.00
Total Current Liabilities
3,301.00
2,625.00
2,532.00
4,586.00
4,163.00
Total Liabilities
3,301.00
2,625.00
2,532.00
4,586.00
4,163.00
Common Equity (Total)
728.00
1,260.00
97.00
1,908.00
3,429.00
Total Shareholders' Equity
728.00
1,260.00
97.00
1,908.00
3,429.00
Total Equity
728.00
1,260.00
97.00
1,908.00
3,429.00
Liabilities & Shareholders' Equity
2,573.00
3,885.00
2,629.00
2,678.00
734.00

About Inspyr Therapeutics

View Profile
Address
31200 Via Colinas
Westlake Village California 91362
United States
Employees -
Website http://www.inspyrtx.com
Updated 07/08/2019
Inspyr Therapeutics, Inc. is a pharmaceutical company, which focuses on the development of prodrug cancer therapeutics for the treatment of solid tumors. The company's prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its technology platform combines a powerful cytotoxin with a patented prodrug delivery system that targets the release of the drug within the tumor.